UCSD Moores Cancer Center | Strategic Alliance Partners

March 22, 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

March 10, 2022

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

February 16, 2022

Michael Choi, MD, discusses the results of the phase 3 GENUINE trial examining ublituximab in combination with ibrutinib vs ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

February 14, 2022

Jennifer M. Matro, MD provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice.

February 08, 2022

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

February 07, 2022

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

February 03, 2022

Developing BRAF inhibitors for patients with atypical class II and III mutations has become an exciting area of research.

January 26, 2022

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

January 18, 2022

Paying particular attention to the specific type of gene mutation on a molecular testing report is critical in an era of increasing genomic complexity in non–small cell lung cancer.

January 17, 2022

Michael Choi, MD, discusses future research directions in chronic lymphocytic leukemia.

January 13, 2022

Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.

January 06, 2022

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

January 05, 2022

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

December 22, 2021

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

December 14, 2021

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

November 15, 2021

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

November 09, 2021

An increased understanding of the biology of non–small cell lung cancer has led to a significant increase in therapeutic options for patients.

August 12, 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

August 12, 2021

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

July 30, 2021

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.